Обзор Intercept Pharmaceuticals: so that the liver does not hurt
Intercept Pharmaceuticals (NASDAQ: ICPT) - a biotechnology company from the USA, which in her research focuses on solving the problems of liver diseases. The business was founded in 2002 and listed its shares on the Nasdaq in 2012 - now they are trading close to the all-time low in the area 15 $. Where does the money come from? Like most biotechs, the company develops medicines and prepares them for commercialization in the US markets, Canada and Europe. Intercept Pharmaceuticals plans to produce synthetic analogs of bile acids, which will be used in the treatment of chronic liver diseases, such as primary biliary cholangitis, non-alcoholic steatohepatitis, cirrhosis of the liver and others. Portfolio of developed drugs The main developments of the company are based on obeticholic acid (OCA). The drug "Okaliva" based on it was approved by the Food and Drug Administration (FDA) in May 2016 and is prescribed by prescription for the treatment of primary biliary cholangitis. Intercept Pharmaceuticals plans to expand its sales market: filed for FDA approval for fibrosis, associated with non-alcoholic steatohepatitis; the third phase of clinical trials of the drug for use in the treatment of cirrhosis is underway, caused by non-alcoholic steatohepatitis; the second phase of clinical trials is underway for the combination of obeticholic acid and bezofibrate in the treatment of primary biliary cholangitis. The company has also begun preclinical development of a new generation of farnesoid receptor agonists. (FXR). Что плохого Объем коротких позиций в акциях компании, по данным Finviz, exceeds 30%, which puts strong pressure on prices, which have reached historic lows this year. Commitments have been growing since 2019 and as of August 2021 are 139% from business assets. The greater the debt, тем больше денег будет уходить на его обслуживание — в случае повышения процентной ставки …
Обзор Intercept Pharmaceuticals: so that the liver does not hurt Read more